Lyophilisation is one of the most effective ways of giving to biotechnologically produced drugs greater stability and a longer shelf-life, while still maintaining their effectiveness. For drug manufacturers, the challenge may at first appear daunting, but it is one that must be met if the compounds being developed are to be successful. Thomas Otto of Vetter Pharma takes a look at what makes lyophilisation and reconstitution viable: the wide range of available systems that can be used as primary packaging for the lyophilised substance, from simple vials to sWFI syringes for reconstitution and special dual-chamber cartridges for pen injector systems for the homecare segment.
https://international-pharma.com/wp-content/uploads/2014/03/Developing…pdf.pdf